OCA
TRVI icon

Octagon Capital Advisors’s Trevi Therapeutics TRVI Stock Holding History

Octagon Capital Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$17.7M Sell
1,485,000
-1,330,000
-47% -$14.9M 1.96% 17
2025
Q4 		$35.2M Hold
2,815,000
– – 4.28% 8
2025
Q3 		$25.8M Sell
2,815,000
-857,000
-23% -$6.43M 3.9% 9
2025
Q2 		$20.1M Buy
3,672,000
+350,000
+11% +$2.18M 4.41% 9
2025
Q1 		$20.9M Buy
+3,322,000
New +$15.8M 4.04% 5

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Octagon Capital Advisors's TRVI Position: Q1 2026 in Review

Octagon Capital Advisors reduced its Trevi Therapeutics (TRVI) stake by 47% in Q1 2026, selling an estimated $14.9M and leaving 1,485,000 shares worth $17.7M. The position accounts for 1.96% of the portfolio, ranked #17.

Octagon Capital Advisors first reported a position in TRVI in Q1 2025 and has held it in 5 quarters since. The position peaked at $35.2M in Q4 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • Octagon Capital Advisors held 1,485,000 shares of Trevi Therapeutics worth $17.7M as of Q1 2026.
  • Octagon Capital Advisors sold 1,330,000 Trevi Therapeutics shares in Q1 2026, an estimated $14.9M.
  • Trevi Therapeutics made up 1.96% of Octagon Capital Advisors's portfolio in Q1 2026, its #17 holding.
  • Octagon Capital Advisors first reported a position in Trevi Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Octagon Capital Advisors's Trevi Therapeutics position peaked at $35.2M in Q4 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.